Sign in

You're signed outSign in or to get full access.

Austin Aerts

Chief Financial Officer at SERA PROGNOSTICS
Executive

About Austin Aerts

Austin Aerts (age 38) is Chief Financial Officer of Sera Prognostics. He joined Sera in July 2017, served as interim CFO from June 2023 to November 2023, and was appointed CFO in November 2023. He holds a Master of Accounting from the University of Utah and is an active CPA licensed in Utah. Notable execution contributions include leading finance for Sera’s July 2021 IPO and the February 2025 follow‑on offering. The proxy does not disclose TSR, revenue growth, or EBITDA growth attributable to his tenure.

Past Roles

OrganizationRoleYearsStrategic Impact
Sera Prognostics, Inc.Chief Financial OfficerAppointed Nov 2023; interim CFO Jun–Nov 2023Led finance and capital markets; played key roles in the 2021 IPO and 2025 follow‑on offering
Sera Prognostics, Inc.VP Finance & Corporate ControllerJul 2017–Jun 2023Drove process and internal control improvements, managed vital accounting/finance functions
Myriad Genetics, Inc.Finance department rolesNot disclosedDiagnostics industry finance experience
Ernst & Young LLPAssurance professionalNot disclosedAudited public/private companies including Sera

External Roles

  • No current external board roles or committee positions are disclosed for Mr. Aerts in the proxy biographies.

Fixed Compensation

MetricFY 2022FY 2023
Base Salary ($)230,150 307,627
Option Awards ($)91,089 23,195
Stock Awards ($)645,178
Non‑Equity Incentive ($)57,500 46,798
Other Compensation ($)10,709 13,200
Total ($)389,448 1,035,998

Additional pay settings and changes:

  • Employment agreement dated Nov 6, 2023 set initial CFO base salary at $357,850; company-wide reductions cut his annual base to $304,173 effective Nov 6, 2023.
  • Annual target bonus: 40% in his agreement; reduced to 20% for 2023; target remains 20% for 2024 per the proxy.

Performance Compensation

Plan / MetricWeightingTargetActualPayoutVesting
2023 Annual Incentive Plan (5 corporate metrics: financial goals, outcomes studies advancement, new data assets, expense reductions, process improvements)Not disclosed 20% of base salary (adjusted) $46,798 70% of target Cash, lump sum post‑year

Note: 2024 executive bonus details are disclosed for other NEOs but not for Mr. Aerts individually.

Equity Ownership & Alignment

Outstanding equity awards (as of Dec 31, 2023):

Grant DateInstrumentExercisable (#)Unexercisable (#)Strike ($)ExpirationRSUs Unvested (#)RSU Market Value ($)
02/27/2020Stock Option23,324 1,014 1.77 02/27/2030
08/20/2020Stock Option2,055 350 1.77 08/20/2030
03/08/2021Stock Option59,524 27,056 5.32 03/08/2031
08/26/2021Stock Option2,917 2,083 9.95 08/26/2031
03/23/2022Stock Option17,500 22,500 3.75 03/23/2032
03/06/2023Stock Option1,723 7,467 3.80 03/06/2033
03/06/2023RSUs5,810 34,744
11/06/2023RSUs125,000 747,500
11/06/2023RSUs (modified)210,000 1,255,800

Vesting schedules and selling pressure indicators:

  • RSUs granted 11/06/2023 (125,000) vest over two years: 1/8 quarterly for eight quarters following grant (quarterly installments). This cadence can create predictable supply into the float absent 10b5‑1 plans.
  • RSUs (210,000) originally four‑year quarterly vesting were modified on Mar 15, 2024 to accelerate 26,250 RSUs and vest the remaining unvested shares in 13 quarterly installments beginning Jun 7, 2024, adding incremental quarterly supply.
  • Options primarily vest monthly (1/48 or tiered schedules), with a meaningful pool already exercisable.

Hedging/pledging:

  • Company policy prohibits short sales, the use of company stock to secure a margin or other loan (pledging), transactions involving collars or other hedging devices, and trading public options on company stock by employees and directors. Quarterly trading blackouts and pre‑clearance apply.

Beneficial ownership disclosure:

  • The 2025 proxy provides aggregate ownership for “all current executive officers and directors” that includes Mr. Aerts, but does not break out his individual percentage/holding. Individual NEO ownership detail for Mr. Aerts is not in the 2025 table; 2023/2024 proxies list his outstanding awards (above).

Employment Terms

TermDetail
Employment AgreementExecuted Nov 6, 2023 for CFO role; initial base $357,850; base reduced to $304,173 effective Nov 6, 2023 under cost reduction; target bonus 40% in agreement (adjusted to 20% for 2023; 20% for 2024 per proxy)
SeveranceIf terminated without cause or for Good Reason: lump‑sum equal to six months’ base salary on the 60th day; health insurance reimbursement up to 12 months or earlier COBRA exhaustion/eligibility under new employment
Equity AccelerationUpon qualifying termination: 37.5% of unvested equity vests; if termination occurs within 30 days prior to or within 12 months after a Change of Control (as defined in Sera plans), 100% of unvested equity vests (double‑trigger with a springing window)
Death/Disability PaymentIf death/disability and company has previously achieved $10,000,000 annual gross revenue, lump‑sum equal to six months’ base salary (subject to no insurance benefits otherwise provided)
ClawbackCompany‑wide clawback policy adopted Oct 2, 2023 to recover excess incentive comp tied to erroneously reported financials after a restatement, regardless of misconduct; applies to covered officers (includes CFO)
Insider Trading ControlsProhibits hedging, short sales, margin loans/pledges; requires pre‑clearance for trades; quarterly and event‑based blackouts

Investment Implications

  • Pay mix has shifted toward equity: 2023 saw substantial RSU grants alongside reduced cash compensation, improving alignment with long‑term shareholder value but increasing predictable quarterly supply as RSUs vest (1/8 quarterly for the 125k grant; 13 quarterly installments for the modified 210k grant beginning June 2024). Monitor Form 4s/10b5‑1 plans for selling cadence.
  • Retention and change‑of‑control dynamics: 6‑month salary severance plus 37.5% equity acceleration on standard qualifying terminations; 100% acceleration within the CoC window indicates double‑trigger protection with enhanced CoC economics—balanced retention yet potential full equity release in transactions.
  • Governance and risk controls: SEC/Nasdaq‑compliant clawback and strict anti‑hedging/anti‑pledging policy are positive alignment signals; equity award modification (RSU acceleration in Mar 2024) is a governance consideration to monitor for precedent and rationale.
  • Execution track record: Led finance for the 2021 IPO and 2025 follow‑on offering, evidencing capital markets competency for funding growth; no TSR or financial performance metrics are disclosed specific to his tenure in the proxy.